Health

New Research Finds Moderna COVID-19 Vaccine “Highly Effective” Against All SARS-CoV-2 Virus Variants

COVID Vaccine Effective Response Success

Kaiser Permanente study shows 2-dose Moderna vaccine is highly effective against COVID-19 hospitalization, but protection against delta infection decreases over time.

Kaiser Permanente research published today (December 15, 2021) in The British Medical Journal showed 2 doses of Moderna COVID-19 vaccine were highly effective against all SARS-CoV-2 variants; however, vaccine effectiveness against the delta variant moderately declined with increasing time after vaccination.

“We conducted a previous study that showed the high effectiveness of the 2-dose Moderna COVID-19 vaccine, but as the delta variant became predominant in early summer of 2021, questions arose about effectiveness against variants,” said the lead author of the study, Katia Bruxvoort, PhD, an adjunct investigator with the Kaiser Permanente Southern California Department of Research & Evaluation.

“This study confirmed effectiveness against all variants during the study period, although we did find a drop in effectiveness over time against delta infection, from 94% effectiveness in the first 2 months after vaccination to 80% effectiveness after 6 months. Protection against hospitalization due to the delta variant remained high at 98% effectiveness.”

At Kaiser Permanente in Southern California, molecular diagnostic testing for SARS-CoV-2 is free for members who request it regardless of whether they have COVID-19 symptoms. Testing also is done prior to hospital admission and many medical procedures. Beginning in March 2021, Kaiser Permanente in Southern California began sending positive SARS-CoV-2 specimens from both symptomatic and asymptomatic people to a contracted laboratory for whole genome sequencing.

This study, funded by Moderna, included 8,153 people who tested positive for SARS-CoV-2, with specimens collected from March 1 to July 27, 2021. Among them, 91.3% were unvaccinated, 1.4% had received 1 dose of Moderna COVID-19 vaccine, and 7.3% had received 2 doses of the Moderna COVID-19 vaccine.

Variants were identified for 5,186 of those samples; 39.4% were delta, 27.7% alpha, 11.4% epsilon, 6.9% gamma, 2.2% iota, 1.4% mu, and 11.1% other variants. At the time of this study, the omicron variant had not yet been detected in the Southern California region.

The researchers compared people who tested positive with those who tested negative. Researchers found:

  • The 2-dose Moderna COVID-19 vaccine effectiveness against infection by variant:
    • Delta: 86.7%
    • Mu: 90.4%
    • Alpha: 98.4%
    • Other identified variants: 96 to 98%
  • People who received the 2-dose Moderna COVID-19 vaccine were strongly protected against COVID-19 hospitalization associated with the delta variant:
    • Vaccine effectiveness against delta hospitalization was high at 97.5%
    • Vaccine effectiveness against hospitalization for non-delta variants was not estimated because there were no hospitalizations with non-delta variants identified among vaccinated people
  • Among people who had received the 2-dose Moderna COVID-19 vaccine, no hospitalized deaths occurred
  • Vaccine effectiveness of 2 doses of Moderna COVID-19 vaccine against delta infection was 87.9% among people ages 18 to 64, and 75.2% among people ages 65 and older

“While this study provides reassuring evidence of the effectiveness of 2 doses of Moderna COVID-19 vaccine in preventing COVID-19 infection and hospitalization due to variants including delta, it also has implications for booster shots,” said the study’s senior author, Hung Fu Tseng, PhD, a researcher with the Kaiser Permanente Southern California Department of Research & Evaluation. “The findings of moderately reduced vaccine effectiveness of Moderna COVID-19 vaccine over time against delta infection supports current booster dose recommendations.”

Reference: “Effectiveness of mRNA-1273 against Delta, Mu, and other emerging variants: an test-negative study” by Katia J Bruxvoort, Lina S Sy, Lei Qian, Bradley K Ackerson, Yi Luo, Gina S Lee, Yun Tian, Ana Florea, Michael Aragones, Julia E Tubert, Harpreet S Takhar, Jennifer H Ku, Yamuna D Paila, Carla A Talarico and Hung Fu Tseng, 15 December 2021, The British Medical Journal.
DOI: 10.1136/bmj-2021-068848

Share

View Comments

  • Two statements from the above article:

    1. "Kaiser Permanente research published today (December 15, 2021) in The British Medical Journal "

    2. "This study, funded by Moderna, "

Recent Posts

Never-Before-Seen Molecule: Webb Reveals a “Hot Saturn” Exoplanet Atmosphere

New Webb Space Telescope observations of WASP-39 b reveal a never-before-seen molecule in the atmosphere…

December 2, 2022

What Predicts Parents’ Desire for More Children?

There are no differences in the desire for more children or the ideal family, according…

December 2, 2022

Anti-Aging Medicines Seek To Eliminate “Zombie” Cells – But Could This Be Dangerous?

Senescent Cells Help To Heal Damaged Tissues According to a recent study from the University…

December 2, 2022

A New Dawn for Prosthetics: Engineers Light the Way To Nerve-Operated Prosthetics of the Future

A multidisciplinary UNSW team has discovered a method to transform nerve impulses into light, paving…

December 2, 2022

Lost for Centuries: Scientists Discover Texts From an Ancient Astronomical Catalog

Written over 2000 years ago, the Hipparchus Star Catalogue is the oldest known attempt to…

December 2, 2022

Positive Clinical Results for Alzheimer’s Amyloid-Clearing Drug – Lecanemab Poised for FDA Approval

Positive results from new amyloid-clearing drug represent a starting point for Alzheimer’s treatment, while combination…

December 2, 2022